ArticleScientific reports2017
New natural products identified by combined genomics-metabolomics profiling of marine Streptomyces sp. MP131-18.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Targeted identification of new phaterpenes and elucidation of the relevant biosynthetic pathway inSynthetic and systems biotechnology · 2026Article
- Chemical Investigation of the Global RegulatorMarine drugs · 2026Article
- NRPS and PKS pathways in actinomycetes: A review of biosynthetic diversity and bioactive potential.Current research in pharmacology and drug discovery · 2026Review
- Last Decade Insights in Exploiting Marine Microorganisms as Sources of New Bioactive Natural Products.Marine drugs · 2025Review
- Exploring omics strategies for drug discovery fromFrontiers in pharmacology · 2025Review
- Synthesis of the 5/5-spiroindimicin alkaloids: development of a general synthetic approach and biological investigations.Organic & biomolecular chemistry · 2024Article
- Streptomyces-Fungus Co-Culture Enhances the Production of Borrelidin and Analogs: A Genomic and Metabolomic Approach.Marine drugs · 2024Article
- Unveiling biosynthetic potential of an Arctic marine-derived strain Aspergillus sydowii MNP-2.BMC genomics · 2024Article
- Integrative Genomics and Bioactivity-Guided Isolation of Novel Antimicrobial Compounds fromMolecules (Basel, Switzerland) · 2024Article
- MarineMarine drugs · 2024Review
- Pan-Omics in Sheep: Unveiling Genetic Landscapes.Animals : an open access journal from MDPI · 2024Review
- Natural Products and Pharmacological Properties of Symbiotic Bacillota (Firmicutes) of Marine Macroalgae.Marine drugs · 2023Review
- Marine-DerivedMicroorganisms · 2023Article
- Draft Genome Sequence of the Marine-Derived, Anticancer Compound-Producing BacteriumMicrobiology resource announcements · 2023Article
- Metabologenomics analysis ofFrontiers in microbiology · 2023Article
- Functional Studies and Revision of the NFAT-133/TM-123 Biosynthetic Pathway inACS chemical biology · 2022Article
- Novel Alkaloids from Marine Actinobacteria: Discovery and Characterization.Marine drugs · 2021Review
- Marine Indole Alkaloids-Isolation, Structure and Bioactivities.Marine drugs · 2021Review
- Marine Pyrrole Alkaloids.Marine drugs · 2021Review
- Applications and Restrictions of Integrated Genomic and Metabolomic Screening: An Accelerator for Drug Discovery from Actinomycetes?Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine actinobacteria are drawing more and more attention as a promising source of new natural products. Here we report isolation, genome sequencing and metabolic profiling of new strain Streptomyces sp. MP131-18 isolated from marine sediment sample collected in the Trondheim Fjord, Norway. The 16S rRNA and multilocus phylogenetic analysis showed that MP131-18 belongs to the genus Streptomyces. The genome of MP131-18 isolate was sequenced, and 36 gene clusters involved in the biosynthesis of 18 different types of secondary metabolites were predicted using antiSMASH analysis. The combined genomics-metabolics profiling of the strain led to the identification of several new biologically active compounds. As a result, the family of bisindole pyrroles spiroindimicins was extended with two new members, spiroindimicins E and F. Furthermore, prediction of the biosynthetic pathway for unusual α-pyrone lagunapyrone isolated from MP131-18 resulted in foresight and identification of two new compounds of this family - lagunapyrones D and E. The diversity of identified and predicted compounds from Streptomyces sp. MP131-18 demonstrates that marine-derived actinomycetes are not only a promising source of new natural products, but also represent a valuable pool of genes for combinatorial biosynthesis of secondary metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.